Protect NIH's DNA advisory committee

Zach N. Adelman; Lorraine M. Albritton; Kathleen Boris-Lawrie; Michael J. Buchmeier; Paula Cannon; Mildred Cho; David DiGiusto; J. Kevin Donahue; Howard J. Federoff; Marie Louise Hammarskjold; Angelica D. Hardison; Patrick Hearing; Benhur Lee; Dean Anthony Lee; Matthew H. Porteus; Lainie Friedman Ross; Susan R. Ross; Dawn P. Wooley; Laurie Zoloth

doi:10.1126/science.aav2483

Protect NIH's DNA advisory committee

Zach N. Adelman, Lorraine M. Albritton, Kathleen Boris-Lawrie, Michael J. Buchmeier, Paula Cannon, Mildred Cho, David DiGiusto, J. Kevin Donahue, Howard J. Federoff, Marie Louise Hammarskjold, Angelica D. Hardison, Patrick Hearing, Benhur Lee, Dean Anthony Lee, Matthew H. Porteus, Lainie Friedman Ross, Susan R. Ross, Dawn P. Wooley, Laurie Zoloth

Veterinary and Biomedical Sciences

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	409-410
Number of pages	2
Journal	Science
Volume	362
Issue number	6413
DOIs	https://doi.org/10.1126/science.aav2483
State	Published - Oct 26 2018

Bibliographical note

Funding Information:
The Recombinant DNA Advisory Committee (RAC) was founded at the behest of concerned scientists based on the principle that public trust of advanced technologies must be earned through transparency and expert deliberation. For more than 40 years, the RAC has served as custodian of the National Institutes of Health (NIH) guidelines, with responsibilities in human gene therapy evolving from regulatory to advisory to the NIH and Food and Drug Administration (FDA). However, the NIH director and FDA commissioner have proposed the elimination of RAC review of human gene therapy protocols (1, 2).

Access

10.1126/science.aav2483

OpenUrl availability

Full text

Cite this

Adelman, Z. N., Albritton, L. M., Boris-Lawrie, K., Buchmeier, M. J., Cannon, P., Cho, M., DiGiusto, D., Donahue, J. K., Federoff, H. J., Hammarskjold, M. L., Hardison, A. D., Hearing, P., Lee, B., Lee, D. A., Porteus, M. H., Ross, L. F., Ross, S. R., Wooley, D. P., & Zoloth, L. (2018). Protect NIH's DNA advisory committee. Science, 362(6413), 409-410. https://doi.org/10.1126/science.aav2483

@article{2be4d9e98c08474aa4626819830c0ce4,

title = "Protect NIH's DNA advisory committee",

author = "Adelman, {Zach N.} and Albritton, {Lorraine M.} and Kathleen Boris-Lawrie and Buchmeier, {Michael J.} and Paula Cannon and Mildred Cho and David DiGiusto and Donahue, {J. Kevin} and Federoff, {Howard J.} and Hammarskjold, {Marie Louise} and Hardison, {Angelica D.} and Patrick Hearing and Benhur Lee and Lee, {Dean Anthony} and Porteus, {Matthew H.} and Ross, {Lainie Friedman} and Ross, {Susan R.} and Wooley, {Dawn P.} and Laurie Zoloth",

note = "Funding Information: The Recombinant DNA Advisory Committee (RAC) was founded at the behest of concerned scientists based on the principle that public trust of advanced technologies must be earned through transparency and expert deliberation. For more than 40 years, the RAC has served as custodian of the National Institutes of Health (NIH) guidelines, with responsibilities in human gene therapy evolving from regulatory to advisory to the NIH and Food and Drug Administration (FDA). However, the NIH director and FDA commissioner have proposed the elimination of RAC review of human gene therapy protocols (1, 2).",

year = "2018",

month = oct,

day = "26",

doi = "10.1126/science.aav2483",

language = "English (US)",

volume = "362",

pages = "409--410",

journal = "Science",

issn = "0036-8075",

publisher = "American Association for the Advancement of Science",

number = "6413",

}

TY - JOUR

T1 - Protect NIH's DNA advisory committee

AU - Adelman, Zach N.

AU - Albritton, Lorraine M.

AU - Boris-Lawrie, Kathleen

AU - Buchmeier, Michael J.

AU - Cannon, Paula

AU - Cho, Mildred

AU - DiGiusto, David

AU - Donahue, J. Kevin

AU - Federoff, Howard J.

AU - Hammarskjold, Marie Louise

AU - Hardison, Angelica D.

AU - Hearing, Patrick

AU - Lee, Benhur

AU - Lee, Dean Anthony

AU - Porteus, Matthew H.

AU - Ross, Lainie Friedman

AU - Ross, Susan R.

AU - Wooley, Dawn P.

AU - Zoloth, Laurie

N1 - Funding Information: The Recombinant DNA Advisory Committee (RAC) was founded at the behest of concerned scientists based on the principle that public trust of advanced technologies must be earned through transparency and expert deliberation. For more than 40 years, the RAC has served as custodian of the National Institutes of Health (NIH) guidelines, with responsibilities in human gene therapy evolving from regulatory to advisory to the NIH and Food and Drug Administration (FDA). However, the NIH director and FDA commissioner have proposed the elimination of RAC review of human gene therapy protocols (1, 2).

PY - 2018/10/26

Y1 - 2018/10/26

UR - http://www.scopus.com/inward/record.url?scp=85055616683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055616683&partnerID=8YFLogxK

U2 - 10.1126/science.aav2483

DO - 10.1126/science.aav2483

M3 - Letter

C2 - 30361364

AN - SCOPUS:85055616683

SN - 0036-8075

VL - 362

SP - 409

EP - 410

JO - Science

JF - Science

IS - 6413

ER -

Protect NIH's DNA advisory committee

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this